Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.